Shin CBL‑514 na ƙona mai ainihi? Ga abin da muka sani
Burin farko na binciken mataki na biyu da aka gudanar a 2025 kan CBL‑514 ba shi ne rage nauyin jiki ba, kuma ba ƙona mai a zahiri ba. An auna adadin mahalarta da suka rasa aƙalla mililita 150 na kitse a ƙarƙashin fata a ƙirji, ta hanyar ultrasound. A makonni 8 bayan ƙarshe‑ƙarshe na magani, 69.6 % (16/23) na mahalarta da suka karɓi CBL‑514 sun kai wannan ragi, yayin da 0 % (0/16) a rukunin placebo (P < .001). Matsalar ita ce adadin mahalarta ya ragu yayin da aka bibiyi lokaci; ƙungiyar da ta bi ka’ida ta ƙunshi mutane 30 kacal, kuma matsakaicin nauyin jiki bai ragu ba.
Ba shawarwarin likita ba ne. CBL‑514 yana cikin gwaje‑gwajen bincike, ba a amince da shi ta FDA ba, kuma ba kari ba ne.
Menene CBL‑514 (kuma menene ba shi ba)
CBL‑514 (ba “CL‑514”) wani ƙaramin sinadari ne da kamfanin Caliway Biopharmaceuticals ke ƙirƙira. Masu bincike na saka shi a cikin ƙashin kitse – a wannan yanayin a ƙirjin – ba a shan shi ba, kuma ba samfurin kasuwa ba ne. Takardun ba su bayyana cikakken tsarin sinadarin ba.
Ana danganta CBL‑514 da allurar lipolysis wadda ke kashe ɗan gunkin kitse (adipocytes). Ba ya ƙara saurin metabolism ko ƙona kalori kai tsaye. An ambaci wasu hujjoji kamar hana DYRK1b da ƙara caspase‑3 da Bax/Bcl‑2, amma waɗannan su ne rahotanni na ƙananan gwaje‑gwaje da ba a wallafa su ba. Binciken mataki na biyu da aka gudanar a baya (Goodman et al., 2022) ya kasance ƙanana kuma ba a yi amfani da placebo ba.
Takarda: Gold M, et al. Aesthetic Surgery Journal. 2025;45(6):611‑620. Open access on PMC | PubMed | DOI | NCT04897412.
Tsarin gwajin a taƙaice
- Mataki na biyu, rarrabuwa 2:1, single‑blind (masu halarta suna makale; masu bincike da masu ba da tallafi ba su makale ba). An kwatanta da placebo (saline).
- Cibiyoyi biyar a Amurka da Australia, daga Fabrairu 2022 zuwa Maris 2023.
- Magani ya ƙunshi allura 25‑50 µL na 2.4 mg/mL (har zuwa 600 mg) a cikin lokutan mako 4, da bibiyar mako 4 da 8 bayan ƙarshe.
- An auna ƙimar kitse daga kaurin ultrasound a maki 4 a yanki na 300 cm².
- An raba mahalarta 76 (50 CBL‑514, 26 placebo); an yi magani ga 75 (49 CBL‑514, 26 placebo).
Sakamakon da suka fito (ITT)
≥150 mL ragi (buri na farko)
| Lokaci | CBL‑514 | Placebo | P |
|---|---|---|---|
| Makon 4 | 63.9 % (23/36) | 17.4 % (4/23) | < .001 |
| Makon 8 | 69.6 % (16/23) | 0 % (0/16) | < .001 |
≥200 mL ragi
- Makon 4: 58.3 % (21/36) vs 8.7 % (2/23), P < .001.
- Makon 8: 60.9 % (14/23) vs 0 % (0/16), P < .001.
Exploratory ≥250 mL
44.4 % (16/36) a makon 4 da 52.2 % (12/23) a makon 8 a CBL‑514; babu wani mahalarta placebo da ya kai wannan ragi.
Canjin matsakaicin ƙimar kitse (LS) vs farawa (CBL‑514)
- Makon 4: ‑199.80 mL
- Makon 8: ‑209.46 mL
- Banbanci tsakanin ƙungiyoyi: ‑206.62 mL (95 % CI ‑276.09 zuwa ‑137.16) a makon 4, da ‑216.28 mL (95 % CI ‑288.28 zuwa ‑144.28) a makon 8.
Per‑protocol (n = 30 kacal)
- Makon 4: ‑314.70 mL
- Makon 8: ‑279.45 mL
- Banbanci tsakanin ƙungiyoyi: ‑312.08 mL da ‑276.83 mL. Waɗannan ƙididdigar sun fi girma, amma ƙungiyar PP ƙanana ce kuma an zaɓi ta ne daga waɗanda suka kammala tare da nauyi mai ɗorewa.
Mafi girma guda ɗaya shi ne > 750 mL a wani mahalar CBL‑514 – ba misali na yau da kullum ba.
Alluran zuwa manufa
Daga cikin mahalarta 28 na CBL‑514 da suka kai ≥150 mL, 42.9 % (12/28) sun sami wannan ragi bayan magani ɗaya, 35.7 % (10/28) bayan biyu, wanda ke nuni da 78.6 % a haɗe. A ƙungiyar PP, 44.4 % (8/18) bayan ɗaya, 27.8 % (5/18) bayan biyu.
Gadar nauyin jiki
Wannan ƙimar kitse a yanki ne, ba ƙona kitse gaba ɗaya ba. Matsakaicin nauyin jiki a rukunin CBL‑514 ya ƙaru da +0.45 kg a makon 4 da +0.02 kg a makon 8. A placebo an samu ‑0.76 kg da ‑0.26 kg. Marubutan sun bayyana babu canjin muhimmanci a matsakaicin nauyi ko BMI, kuma sun nuna ragowar kitse a yanki ya faru ko da a wasu mahalarta da suka ƙaru da fiye da 1 kg (ba a nuna cikakken bayanin ba). Bayanai suna nuni da kadanan canjin girman ƙirji, ba da sauƙaƙan jiki ba.
Matsalar adadi
Daga cikin mahalarta 75 da aka yi magani, 38 sun kammala binciken; 37 (49.3 %) ba su kammala ba. Dalilan sun haɗa da:
- Rasa bin jadawalin (6)
- Janyewa da kansu (7)
- Rashin daidaiton nauyi (7)
- Rashin halarta a lokutan duba (6)
- Matsalolin lafiya da suka taso sakamakon magani (4)
Wannan dalilin ne ya sa adadin mahalarta CBL‑514 ya ragu daga 36 zuwa 23, kuma placebo daga 23 zuwa 16. Sakamakon 0/16 a makon 8 na placebo yana da ban mamaki, amma yana da alaƙa da ƙananan ƙungiya da ke raguwa. Kashi a makon 8 ya fito ne daga ƙananan mutane, don haka tazarar amincewa (misali 47.08 %–86.79 %) ta fi girma. Marubutan ba su yi gyara don gwaje‑gwaje da yawa ba, kuma girman samfurin gwaji zai iya ƙuntata sahihanci.
Hotuna da ultrasound: abin da ake gani
Takardar ta nuna mata guda biyu, shekaru 49 da 46, waɗanda suka samu ragowar kitse daga 40.85 % zuwa 47.37 % da sauyin nauyi ƙasa da 1 kg. A wacce ke da shekaru 46, kaurin ultrasound a maki 4 ya sauka daga 4.06, 4.20, 3.90, 3.26 cm a farawa zuwa kusan 2 cm ko ƙasa a bibiyoyi biyu. Tsarin 3D ya nuna ragowar a cikin yanki da aka yi magani. Marubutan sun lura da ƙarancin laushin fata a hotunan bayan magani, amma wannan ƙima ne na gani, ba auna ba.
Tsaro: sakamakon TEAE
Kusan kowane mahalarta ya fuskanci TEAE (adverse events) da ya danganci magani, 98‑100 %, ciki har da rukunin placebo. Martani a wurin allura sun haɗa da:
- Ƙura: 71.4 % (CBL‑514) vs 11.5 % (placebo)
- Tsaurara: 61.2 % vs 7.7 %
- Zafi mai tsanani: 18.4 % vs 0 %
Takardar ta ƙara da rabe‑raben tsanani, amfani da maganin zafi, da lokutan warkewa, inda mafi yawan martani suka ɓuya cikin mako 1. Duba cikakken rubutu don ƙididdige cikakken bayani. Masu halarta biyu sun daina shiga saboda tasirin magani. An lura da wani lamari na hyperlipidemia da ake zargin alaka, yayin da wani lamari mai tsanani – metastasis na peritoneal – an ƙayyade ba alaka ba. Ba a samu lalatar fata, kumburi ko raunukan jijiyoyi a wannan rahoton.
Kwatanta da sauran hanyoyin rage kitse (tare da ƙuntatawa)
Marubutan sun ambaci binciken cryolipolysis da suka yi amfani da hanyoyi daban‑daban na aunawa. Wani bincike ya buga ragowar 264.8 mL a ƙirji da flank a makonni 12 bayan zagaye 24, wani kuma ya ba da 39.6 mL a flank a watanni 2 bayan zagaye ɗaya. Sun ce CBL‑514 "yana nuna girma," kuma suka kwatanta sakamako da liposuction. Waɗannan fassarori ne na masu bincike; gwajin CBL‑514 ba ya haɗa gwajin kai‑tsaye da cryolipolysis ko liposuction.
Ƙuntatawa
- Mataki na biyu tare da lokaci ƙasa (makonni 8 bayan magani)
- Tsarin single‑blind, tare da masu bincike da ba su makale ba
- Mai ba da tallafi ya shiga ƙirƙira, nazari, rubutu da yanke shawara don wallafa
- Yawan fita da ƙananan yawan per‑protocol
- Demografiya ba su daidaita ba: 94 % mata a rukunin CBL‑514, 86 % farar fata
- Volume na ultrasound an ƙididdige daga cuboid, ba a auna kitse kai tsaye ba
- Ba a daidaita don gwaje‑gwaje da yawa ba
Gabaɗaya
CBL‑514 ya rage kimar kitse a ƙarƙashin fata na ƙirji idan aka kwatanta da saline a wannan gwaji, tare da tasiri mai girma da ƙididdiga wadda ta fita fili. Ba ya rage nauyin jiki, kuma shaidar ba ta nuna ƙona mai gaba ɗaya. Har yanzu ana buƙatar gwaje‑gwaje masu girma, dogon lokaci da maimaita su daga masu ba da shawara masu zaman kansu, kuma maganin har yanzu yana cikin matakin bincike.